TO 14
Alligator Bioscience carried out a rights issue of units during October – December 2025 (the “Rights Issue”). Each unit issued in the Rights Issue consisted of two (2) ordinary shares and one (1) warrant series TO 14. A total of 226,766,657 warrants series TO 14 were issued in the Rights Issue. In addition, in January 2026 and in connection with the Rights Issue, the Board of Directors of the Company resolved on a directed issue of units in which 18,585,000 warrants series TO 14 in total were issued. The total number of outstanding warrants series TO 14 thus amounts to 245,351,657. Subscription of ordinary shares through utilization of warrants series TO 14 will take place during the period from and including 5 March 2026 up to and including 19 March 2026. If all warrants are exercised, Alligator Bioscience will receive approximately SEK 49 million before issue costs.
Timeline
- ~27 February 2026 – Announcement of exercise price
- 5 March 2026 – 19 March 2026 – Exercise period
- 17 March 2026 – Last day of trading with warrants
Preliminary timeline
| 24 November 2025 | Publication of final terms of the Rights Issue, including Subscription Price |
| 25 November 2025 | Extraordinary general meeting |
| 28 November 2025 | Estimated publication of the Prospectus |
| 28 November 2025 | Last day of trading incl. preferential rights |
| 1 December 2025 | First day of trading excl. preferential rights |
| 2 December 2025 | Record date in the Rights Issue |
| 4 – 15 December 2025 | Trading in unit rights |
| 4 – 18 December 2025 | Subscription period |
| 22 December 2025 | Estimated publication of the outcome of the Rights Issue |
| 4 December 2025 – 13 January 2026 | Trading in paid subscribed units (BTU) |
The application form is available under the tab “Financial reports and other documentation” below. For digital signing with Swedish BankID, please visit Vator Securities’ transaction page.
The application forms are primarily intended for shareholders with directly registered holdings (VP accounts). Shareholders holding shares through a nominee/custodian should subscribe through their nominee.
Video interviews – the Rights Issue
- English video (BioStock): CEO Søren Bregenholt (opens on BioStock)
- Swedish video (Redeye): CFO Johan Giléus (opens on Redeye)